학술논문

CAR-T-Zell-Therapie in der Rheumatologie – Was wissen wir bisher?
Document Type
Original Paper
Source
Zeitschrift für Rheumatologie. 83(6):485-491
Subject
B-Zell Depletion
Autoimmunerkrankungen
Systemischer Lupus erythematodes
Kollagenosen
Immunzelltherapie
B-cell depletion
Autoimmune diseases
Systemic Lupus erythematodes
Collagenosis
Immunecell therapy
Language
German
ISSN
0340-1855
1435-1250
Abstract
Autoreactive B‑cells play a key role in the pathogenesis of autoimmune diseases, such systemic lupus erythematosus (SLE). An efficient depletion of B‑cells therefore plays a special role in autoimmune diseases, especially in cases with a severe course of the disease. Treatment with chimeric antigen receptor (CAR) T‑cells, which was originally developed for the treatment of B‑cell lymphomas and leukemias, provides the possibility to deplete B‑cells even in deep tissues. The initial results from case series with this procedure for SLE, myositis and systemic sclerosis were very positive. This review article gives an overview of the course, mechanism of action, results so far and the research agenda of CAR T‑cell therapy in autoimmune diseases.